Adibendan

This classification denotes a phosphodiesterase inhibitor with the molecular formula C16H14N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E87N3L27KX, chemically known as 5,7-dihydro-7,7-dimethyl-2-(4-pyridyl)pyrrolo(2,3-f)benzimidazol-6(3h)-one but generally known as adibendan, which bears US NIH Compound Identifier 65867. European Medicines Agency schedules Adibendan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05268MIG. The term ADIBENDAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). ADIBENDAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule adibendan under HS 29337900 and SITC 51561. As of Q4 2014, ADIBENDAN remains the US FDA Preferred Term for this commodity. Adibendan bears US NLM identifiers UMLS ID C0050840 and NCI Concept Code C74350. SMILES: O=C1NC2C(C1(C)C)CC1[NH]C(NC1C2)C1CCNCC1.